Evidence map›Paper›PMID 38948022›Full record

ArticleOncology research2024

Trametinib boosts palbociclib's efficacy in breast cancer via autophagy inhibition.

Anguo Wu, Jiao Yan, Ting Su, Chi Feng, Xin Long, Yiru Pan, Rupei Ye, Tian Xia, Hanan Long, Jianming Wu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anguo WuSichuan Key Medical Laboratory of New Drug Discovery and Druggability Evaluation, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, Key Laboratory of Medical Electrophysiology of Ministry of Education, School of Pharmacy, Southwest Medical University, Luzhou, 646000, China.
Jiao YanThe Department of Pathology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
Ting SuThe Department of Pathology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
Chi FengSichuan Key Medical Laboratory of New Drug Discovery and Druggability Evaluation, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, Key Laboratory of Medical Electrophysiology of Ministry of Education, School of Pharmacy, Southwest Medical University, Luzhou, 646000, China.
Xin LongSchool of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, China.
Yiru PanSichuan Key Medical Laboratory of New Drug Discovery and Druggability Evaluation, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, Key Laboratory of Medical Electrophysiology of Ministry of Education, School of Pharmacy, Southwest Medical University, Luzhou, 646000, China.
Rupei YeThe Department of Pathology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
Tian XiaThe Department of Pathology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
Hanan LongThe Department of Pathology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
Jianming WuSichuan Key Medical Laboratory of New Drug Discovery and Druggability Evaluation, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, Key Laboratory of Medical Electrophysiology of Ministry of Education, School of Pharmacy, Southwest Medical University, Luzhou, 646000, China.
Xiuli XiaoThe Department of Pathology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer, a predominant global health issue, requires ongoing exploration of new therapeutic strategies. Palbociclib (PAL), a well-known cyclin-dependent kinase (CDK) inhibitor, plays a critical role in breast cancer treatment. While its efficacy is recognized, the interplay between PAL and cellular autophagy, particularly in the context of the RAF/MEK/ERK signaling pathway, remains insufficiently explored. This study investigates PAL's inhibitory effects on breast cancer using both

Indexed as

AutophagyBreast NeoplasmsPiperazinesPyridinesPyridonesPyrimidinonesXenograft Model Antitumor AssaysAnimalsAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorCell ProliferationCell SurvivalDrug Resistance, NeoplasmDrug SynergismFemaleHumanspalbociclibPiperazinesProtein Kinase InhibitorsPyridinesPyridonesPyrimidinonestrametinibMCF7MDA-MB-468PalbociclibProtective autophagyRAF/MEK/ERKTrametinib

Identifiers

PMID38948022
PMCPMC11209742

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.